ICCM vs. TLSI, PROF, ARAY, DRTS, CVRX, CLPT, QIPT, TELA, BWAY, and KRMD
Should you be buying IceCure Medical stock or one of its competitors? The main competitors of IceCure Medical include TriSalus Life Sciences (TLSI), Profound Medical (PROF), Accuray (ARAY), Alpha Tau Medical (DRTS), CVRx (CVRX), ClearPoint Neuro (CLPT), Quipt Home Medical (QIPT), TELA Bio (TELA), BrainsWay (BWAY), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
TriSalus Life Sciences (NASDAQ:TLSI) and IceCure Medical (NASDAQ:ICCM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.
TriSalus Life Sciences has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -444.30%. IceCure Medical's return on equity of 0.00% beat TriSalus Life Sciences' return on equity.
TriSalus Life Sciences has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
In the previous week, IceCure Medical had 9 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 15 mentions for IceCure Medical and 6 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.70 beat IceCure Medical's score of 0.64 indicating that IceCure Medical is being referred to more favorably in the news media.
IceCure Medical has lower revenue, but higher earnings than TriSalus Life Sciences.
TriSalus Life Sciences presently has a consensus price target of $13.33, suggesting a potential upside of 86.22%. IceCure Medical has a consensus price target of $2.95, suggesting a potential upside of 175.70%. Given TriSalus Life Sciences' higher probable upside, analysts clearly believe IceCure Medical is more favorable than TriSalus Life Sciences.
IceCure Medical received 15 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 94.74% of users gave IceCure Medical an outperform vote.
2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 76.2% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 2.4% of IceCure Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
IceCure Medical beats TriSalus Life Sciences on 8 of the 15 factors compared between the two stocks.
Get IceCure Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IceCure Medical Competitors List
Related Companies and Tools
